Author
Yanfei Guo
Bio: Yanfei Guo is an academic researcher from Centers for Disease Control and Prevention. The author has contributed to research in topics: Population ageing & Disease. The author has an hindex of 1, co-authored 1 publications receiving 1045 citations.
Topics: Population ageing, Disease, Disease burden, Population, Global health
Papers
More filters
TL;DR: The authors in this article found that 30.23% of the total global burden of disease is attributable to disorders in people aged 60 years and older, and the leading contributors to disease burden in older people are cardiovascular diseases, malignant neoplasms (15·1%), chronic respiratory diseases (9·5%), musculoskeletal diseases (7·5), and neurological and mental disorders (6·6%).
1,377 citations
Cited by
More filters
TL;DR: The Global Burden of Diseases, Injuries, and Risk Factors Study 2015 (GBD 2015) as discussed by the authors was used to estimate the incidence, prevalence, and years lived with disability for diseases and injuries at the global, regional, and national scale over the period of 1990 to 2015.
5,050 citations
Camden and Islington NHS Foundation Trust1, University College London2, King's College London3, University of Melbourne4, University of Exeter5, Brighton and Sussex Medical School6, University of Manchester7, Tel Aviv University8, Johns Hopkins University9, University of Michigan10, University of Washington11, Kaiser Permanente12, University of Montpellier13, University of Edinburgh14, Dalhousie University15, University of Southern California16, University of Oslo17, Innlandet Hospital Trust18
TL;DR: The Lancet Commission on Dementia Prevention, Intervention, and Care met to consolidate the huge strides that have been made and the emerging knowledge as to what the authors should do to prevent and manage dementia.
3,826 citations
Harvard University1, University of Cape Town2, King's College London3, Makerere University4, Johns Hopkins University5, University of Washington6, Carter Center7, Emory University8, University of London9, University of Melbourne10, World Psychiatric Association11, Al-Quds University12, Rutgers University13, Peking University14, University of Amsterdam15, University of Health Sciences Lahore16, Dow University of Health Sciences17, University of Ibadan18, University of Liverpool19, Public Health Foundation of India20, Wellcome Trust21, University of Oxford22, Groote Schuur Hospital23, South African Medical Research Council24
1,356 citations
TL;DR: Examination of reported trends in morbidity and mortality in older adults during the past two decades found some evidence for compression of morbidity, but with different methods, these measures are not directly comparable.
707 citations
TL;DR: HZ/su was found to reduce the risks of herpes zoster and postherpetic neuralgia among adults 70 years of age or older.
Abstract: BackgroundA trial involving adults 50 years of age or older (ZOE-50) showed that the herpes zoster subunit vaccine (HZ/su) containing recombinant varicella–zoster virus glycoprotein E and the AS01B adjuvant system was associated with a risk of herpes zoster that was 97.2% lower than that associated with placebo. A second trial was performed concurrently at the same sites and examined the safety and efficacy of HZ/su in adults 70 years of age or older (ZOE-70). MethodsThis randomized, placebo-controlled, phase 3 trial was conducted in 18 countries and involved adults 70 years of age or older. Participants received two doses of HZ/su or placebo (assigned in a 1:1 ratio) administered intramuscularly 2 months apart. Vaccine efficacy against herpes zoster and postherpetic neuralgia was assessed in participants from ZOE-70 and in participants pooled from ZOE-70 and ZOE-50. ResultsIn ZOE-70, 13,900 participants who could be evaluated (mean age, 75.6 years) received either HZ/su (6950 participants) or placebo (69...
647 citations